Perjeta approved for advanced breast cancer
10:00 EDT 11 Jun 2012 | Medical Xpress
(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.
Original Article: Perjeta approved for advanced breast cancer
More From BioPortfolio on "Perjeta approved for advanced breast cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
